Press Releases

Date Title  
Toggle Summary Audentes Therapeutics Expands Senior Leadership Team
Natalie Holles Appointed Chief Operating Officer, Thomas Soloway Appointed Chief Financial Officer and Kevin Baker, Ph.D. Appointed Senior Vice President, Preclinical Development SAN FRANCISCO, CA – September 29, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the
Toggle Summary Audentes Therapeutics Acquires Cardiac Gene Therapy Company Cardiogen Sciences
Audentes Expands Portfolio to Include AAV Gene Therapy for Rare, Genetic Cardiac Diseases including CASQ2-CPVT, an Inherited Arrhythmia with a High Risk of Mortality SAN FRANCISCO, CA – September 1, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and
Toggle Summary Audentes Therapeutics Receives Orphan Drug Designation for AT001 for the Treatment of X-Linked Myotubular Myopathy in the US and Europe
SAN FRANCISCO, CA – August 26, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced that AT001, an investigational product in development for the treatment of
Toggle Summary Audentes Therapeutics To Participate In 2015 Piper Jaffray Genomerx Symposium & 1×1 Day
SAN FRANCISCO, CA – May 14, 2014 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, and John T.
Toggle Summary Audentes Therapeutics Announces New Data To Be Presented At American Society Of Gene And Cell Therapy Annual Meeting
Compelling additional preclinical data further support therapeutic potential of gene therapy products to treat X-Linked Myotubular Myopathy and Pompe Disease SAN FRANCISCO, CA – May 11, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of
Toggle Summary Audentes Therapeutics Appoints Stephen Squinto, Ph.d. To Its Board Of Directors
SAN FRANCISCO, CA – April 21, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced the appointment of Stephen Squinto, Ph.D., to the company’s Board of
Toggle Summary Audentes Therapeutics Joins Global Organizations In Celebrating Rare Disease Day® 2015
New Audentes Patient Advocacy Website Created to Serve Patient Community SAN FRANCISCO, CA – February 26, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced
Toggle Summary Audentes Therapeutics Raises $42.5 Million In Series B Financing
Deerfield, Sofinnova, and Venrock Join Existing Investors to Propel Leading Gene Therapy Company Through Significant Clinical and Corporate Development Milestones SAN FRANCISCO, CA – December 2, 2014 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and
Toggle Summary Audentes Therapeutics To Present At The Piper Jaffray Healthcare Conference
SAN FRANCISCO, CA – November 20, 2014 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced that Matthew Patterson, President and Chief Executive Officer, will
Toggle Summary Audentes Therapeutics Announces Continued Expansion Of Senior Management Team
John T. Gray, Ph.D., Brings Leading Gene Therapy Research and Manufacturing Expertise to Company SAN FRANCISCO, CA – October 1, 2014 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare